A Phase I Study of the Co-administration of VLX-1005 and Argatroban in Healthy Human Subjects

NCT05325346 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

12

Enrollment

INDUSTRY

Sponsor class

Conditions

Heparin-induced Thrombocytopenia

Interventions

DRUG: VLX-1005
DRUG: Argatroban

Sponsor

Veralox Therapeutics

Collaborators

[object Object]